Anticoagulation for Nonvalvular Diseases in Patients with a Limited Prognosis #461

Kim J , Parish AL . Polypharmacy and medication management in older adults. Nurs Clin North Am, 2017; 52(3):457–468; doi: 10.1016/j.cnur.2017.04.007

Johnson MJ , McMillan B , Fairhurst C , et al. Primary thromboprophylaxis in hospices: The association between risk of venous thromboembolism and development of symptoms. J Pain Symptom Manage, 2014; 48(1):56–64; doi: 10.1016/j.jpainsymman.2013.08.016

Holbrook A , Schulman S , Witt DM , et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2012; 141(2 Suppl):e152S–e184S; doi: 10.1378/chest.11-2295

Huisman BAA , Geijteman ECT , Kolf N , et al. Physicians' opinions on anticoagulant therapy in patients with a limited life expectancy. Semin Thromb Hemost, 2021; 47(6):735–744; doi: 10.1055/s-0041-1725115

Kowalewska CA , Noble BN , Fromme EK , et al. Prevalence and clinical intentions of antithrombotic therapy on discharge to hospice care. J Palliat Med, 2017; 20(11):1225–1230; doi: 10.1089/jpm.2016.0487

Ouellet GM , Fried TR , Gilstrap LG , et al. Anticoagulant use for atrial fibrillation among persons with advanced dementia at the end of life. JAMA Intern Med, 2021; 181(8):1121–1123; doi: 10.1001/jamainternmed.2021.1819

Ko D , Lin KJ , Bessette LG , et al. Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010–2020. JAMA Netw Open, 2022; 5(11):e2242964; doi: 10.1001/jamanetworkopen.2022.42964

Huisman BAA , Geijteman ECT , Arevalo JJ , et al. Use of antithrombotics at the end of life: An in-depth chart review study. BMC Palliat Care, 2021; 20(1):110; doi: 10.1186/s12904-021-00786-3

Proietti M , Camera M , Gallieni M , et al. Use and prescription of direct oral anticoagulants in older and frail patients with atrial fibrillation: A multidisciplinary consensus document. J Pers Med, 2022; 12(3):469; doi: 10.3390/jpm12030469

Zabrocka E , Sierko E . Thromboprophylaxis in the end-of-life cancer care: The update. Cancers (Basel), 2020; 12(3):600; doi: 10.3390/cancers12030600

Anderson FA , Spencer FA . Risk factors for venous thromboembolism. Circulation, 2003; 107(23_suppl_1):I9–16; doi: 10.1161/01.CIR.0000078469.07362.E6

Chin-Yee N , Tanuseputro P , Carrier M , et al. Thromboembolic disease in palliative and end-of-life care: A narrative review. Thromb Res, 2019; 175:84–89; doi: 10.1016/j.thromres.2018.12.028

Holmes HM , Bain KT , Zalpour A , et al. Predictors of anticoagulation in hospice patients with lung cancer. Cancer, 2010; 116(20):4817–4824; doi: 10.1002/cncr.25284

Gillon S , Noble S , Ward J , et al. Primary thromboprophylaxis for hospice inpatients: Who needs it?. Palliat Med, 2011; 25(7):701–705.

Chen A , Stecker E , Warden BA . Direct oral anticoagulant use: A practical guide to common clinical challenges. J Am Heart Assoc, 2020; 9(13):e017559; doi: 10.1161/JAHA.120.017559

Hagerty T , Rich MW . Fall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance. Cleve Clin J Med, 2017; 84(1):35–40; doi: 10.3949/ccjm.84a.16016

Shanah L , Kabashneh S , Alkassis S , et al. Use of anticoagulants in patients with non-valvular atrial fibrillation who are at risk of falls. Cureus, 2020; 12(9):e10336; doi: 10.7759/cureus.10336

Hindricks G , Potpara T , Dagres N , et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J, 2021; 42(5):373–498; doi: 10.1093/eurheartj/ehaa612

Gao X , Cai X , Yang Y , et al. Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: A systematic review and meta-analysis. Systematic review. Front Cardiovasc Med, 2021; 8:757087; doi: 10.3389/fcvm.2021.757087

Lindsay J , Dooley M , Martin J , et al. The development and evaluation of an oncological palliative care deprescribing guideline: The ‘OncPal deprescribing guideline.’. Support Care Cancer, 2015; 23(1):71–78.

Bao Y , Wan X , Fu J , et al. The risk of venous thromboembolism in cancer patients receiving chemotherapy: A meta-analysis with systematic review. Ann Transl Med, 2021; 9(4):277; doi: 10.21037/atm-20-3292

Moik F , Englisch C , Pabinger I , et al. Risk assessment models of cancer-associated thrombosis—Potentials and perspectives. Thromb Update, 2021; 5:100075; doi: 10.1016/j.tru.2021.100075

de Winter MA , Dorresteijn JAN , Ageno W , et al. Estimating bleeding risk in patients with cancer-associated thrombosis: Evaluation of existing risk scores and development of a new risk score. Thromb Haemost, 2022; 122(5):818–829; doi: 10.1055/s-0041-1735251

Prandoni P , Carnovali M , Marchiori A; Galilei Investigators . Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med, 2004; 164(10):1077–1083; doi: 10.1001/archinte.164.10.1077